DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.
Nasim AzizgolshaniCurtis Lee PetersenYoudinghuan ChenJoshua J LevyLucas A SalasLaurent PerreardLananh N NguyenBrock C ChristensenPublished in: Clinical epigenetics (2021)
We identified that 5hmC localizes to super-enhancers, and genes commonly implicated in pediatric CNS tumors were differentially hypohydroxymethylated. We demonstrated that distinguishing methylation and hydroxymethylation is critical in identifying tumor-related epigenetic changes. These results have implications for patient prognostication, considerations of epigenetic therapy in CNS tumors, and for emerging molecular neuropathology classification approaches.